Table of Contents
CHAPTER 1 BACKGROUND AND SCIENTIFIC OVERVIEW: ANTIBODIES AND MONOCLONAL ANTIBODIES
- 1.1. What Is an Antibody?
- 1.2. What Is a Monoclonal Antibody?
CHAPTER 2 CURRENT AND EMERGING TECHNOLOGIES: IMPROVING MONOCLONAL ANTIBODY DESIGN AND PRODUCTION
- 2.1. Key Breakthroughs in the First 35 Years of Monoclonal Antibody
Development
- Murine-Derived Monoclonal Antibodies
- Chimeric Monoclonal Antibodies
- Humanized Monoclonal Antibodies
- Fully Human Monoclonal Antibodies
- Antibody Fragments
- Antibody Conjugates
- 2.2. Monoclonal Antibody Libraries and Display Technologies
- Phage Display
- MedImmune (AstraZeneca)
- Dyax
- Crucell
- MorphoSys
- Affitech
- Biosite (Inverness Medical Innovations)
- Affimed Therapeutics
- XOMA
- Ribosome Display
- MedImmune (AstraZeneca)
- Discerna
- Other Library-Based Technologies
- Alexion Pharmaceuticals
- BioInvent International
- Adimab
- MSM Protein Technologies
- Vaccinex
- Morphotek (Eisai Corp. of North America)
- AnaptysBio
- Sorrento Therapeutics
- 2.3. Other Technologies for Designing Monoclonal Antibodies
- Techniques for Improving Hybridoma Production
- Abeome
- New Techniques for Generating Animal-Derived Monoclonal Antibodies
- GENOVAC (Aldevron)
- Epitomics
- North Coast Biologics
- Xori
- Chiome Bioscience
- Humanization Technology
- Abmaxis (Merck)
- Arana Therapeutics
- MRC Technology
- ImmunoGen
- KaloBios Pharmaceuticals
- PDL BioPharma
- XOMA
- Antitope
- Xencor
- Massachusetts Institute of Technology
- Transgenic Mice
- Amgen
- Medarex
- AVANIR Pharmaceuticals
- Regeneron Pharmaceuticals
- Human Hybridoma Technology
- Morphotek (Eisai Corp. of North America)
- Patrys
- Kenta Biotech
- 2.4. Alternative Antibody Formats
- Antibody Fragments
- ESBATech
- MacroGenics
- Genmab
- Synthetic Antibodies
- Ablynx
- Affibody
- Domantis (GlaxoSmithKline)
- AdAlta
- Enzon Pharmaceuticals/Micromet
- Arana Therapeutics
- Bispecific Antibodies
- Elusys Therapeutics
- Micromet
- TRION Pharma
- Affimed Therapeutics
- Affitech/Pharmexa
- Biotecnol
- Other Antibodies That Enhance Effector Function
- BioWa
- MacroGenics
- Tolerx
- Vaccibody
- InNexus Biotechnology
- Xencor
- 2.5. Antibody Conjugates
- Antibody-Radioisotope Conjugates
- Affibody
- PBL Therapeutics
- Aduro BioTech
- Antibody-Drug Conjugates
- Medarex
- HERMES Biosciences
- Celldex Therapeutics
- Scancell
- Paladin Labs
- Antibody-Toxin Conjugates
- 2.6. Technologies for Improving Monoclonal Antibody Characteristics
- Protein Engineering
- Applied Molecular Evolution (Eli Lilly)
- Arana Therapeutics
- Morphotek
- MilleGen/Accuro Biologics
- Facet Biotech
- Xencor
- Merus
- Algonomics
- f-star
- PEGylation
- Alternatives to PEGylation
- Glycosylation
- GlycArt (Roche)
- GlycoFi (Merck)
- Glycotope
- Synageva BioPharma
- LFB
- Alternative Modes of Administration
- Altus Pharmaceuticals
- Baxter BioPharma Solutions
CHAPTER 3 MARKETED AND EMERGING MONOCLONAL ANTIBODIES: PRESENT AND FUTURE THERAPEUTICS
- 3.1. Approved Therapeutic Monoclonal Antibodies
- Profiles of Therapeutic Monoclonal Antibodies Approved for Marketing
- Orthoclone OKT3 (Muromonab-CD3) (1986)
- ReoPro (Abciximab) (1994)
- Rituxan (Rituximab) (1997)
- Zenapax (Daclizumab) (1997)
- Simulect (Basiliximab) (1998)
- Synagis (Palivizumab) (1998)
- Remicade (Infliximab) (1998)
- Herceptin (Trastuzumab) (1998)
- Mylotarg (Gemtuzumab Ozogamicin) (2000)
- Campath (Alemtuzumab) (2001)
- Zevalin (Ibritumomab Tiuxetan) (2002)
- Humira (Adalimumab) (2002)
- Xolair (Omalizumab) (2003)
- Bexxar (Tositumomab) (2003)
- Raptiva (Efalizumab) (2003)
- Erbitux (Cetuximab) (2004)
- Avastin (Bevacizumab) (2004)
- Tysabri (Natalizumab) (2006)
- Lucentis (Ranibizumab) (2006)
- Vectibix (Panitumumab) (2006)
- Soliris (Eculizumab) (2007)
- Cimzia (Certolizumab Pegol) (2008)
- Ilaris (Canakinumab) (2009)
- 3.2. Monoclonal Antibodies in Development for Cancer
- Unconjugated Monoclonal Antibodies for Cancer
- Genmab
- Medarex
- Biogen Idec
- Genentech
- Human Genome Sciences
- Pfizer
- Wilex
- Immunomedics
- ImClone Systems (Eli Lilly)
- Morphotek (Eisai Corp. of North America)
- Antisoma
- Micromet
- UCB
- AVEO Pharmaceuticals
- Lpath
- Northwest Biotherapeutics
- Anti-idiotype Monoclonal Antibodies for Cancer
- Menarini Group
- Onyvax
- Conjugated Monoclonal Antibodies for Cancer
- Active Biotech
- Antisoma
- ImmunoGen
- Immunomedics
- MedImmune
- Seattle Genetics
- Celldex Therapeutics/Curagen
- 3.3. Monoclonal Antibodies in Development for Immunological Diseases
- Human Genome Sciences
- Novartis
- UCB
- Amgen
- Biogen Idec/Genentech
- MedImmune
- Genmab
- Millennium Pharmaceuticals (Takeda Pharmaceutical)
- Medarex
- NovImmune
- BioTie Therapies
- Micromet
- ZymoGenetics/Novo Nordisk
- Glenmark Pharmaceuticals
- CSL
- LigoCyte Pharmaceuticals
- Sanofi-Aventis/Kyowa Hakko Kirin
- 3.4. Monoclonal Antibodies in Development for Infectious Diseases
- Novartis
- MedImmune
- Human Genome Sciences
- Taimed Biologics
- Medarex
- Elusys Therapeutics
- Emergent BioSolutions
- Crucell
- Progenics Pharmaceuticals
- Roche
- Genmab
- Theraclone Sciences
- iBioPharma
- 3.5. Monoclonal Antibodies in Development for Cardiovascular Diseases
- Ablynx
- ThromboGenics/BioInvent International
- Affimed Therapeutics
- Lexicon Pharmaceuticals
- 3.6. Other Therapeutic Antibodies in Development
- Amgen
- Elan/Wyeth
- Eli Lilly
- Pfizer
- Others
CHAPTER 4 BUSINESS AND STRATEGIC OUTLOOK: MARKET POTENTIAL FOR MONOCLONAL ANTIBODIES AND TRENDS IN THE FIELD
- 4.1. General Trends
- 4.2. The Market for Therapeutic Monoclonal Antibodies
- Cancer: Solid Tumors
- Cancer: Non-Hodgkin' s Lymphoma
- Immune and Inflammatory Diseases
- Transplant Rejection
- Rheumatoid Arthritis
- Crohn' s Disease
- Psoriasis
- Lupus
- Multiple Sclerosis
- Asthma
- Other Emerging Markets
- Age-Related Macular Degeneration
- HIV
- Alzheimer' s Disease
CHAPTER 5
Survey Results and Analysis
REFERENCES
COMPANY INDEX WITH WEB ADDRESSES
| 
View Cart
